Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Author:
Publish date:

Pfizer's  (PFE) - Get Report  $14 billion dollar acquisition of Medivation  (MDVN)  is a strong purchase that might help the company 'get its groove back,' according to TheStreet's Jim Cramer. He finds it interesting that Pfizer was willing to pay more for Medivation than Sanofi  (SNY) - Get Report wanted to pay for the company, which shows how much Pfizer is interested in building up its oncology business. Cramer wonders if Sanofi will now be interested in adding to its stake in Regeneron (REGN) - Get Report .